AR and prostate carcinoma: This study also showed that BET inhibitors such as JQ-1 and iBET-151 could reduce the viability of AR-positive prostate cancer cells, which differs from the findings of Sakshi Goel et al., who reported that JQ-1 suppressed the viability of VCaP and 22RV1 cells [37].